Drug Profile
Ribavirin elaidate
Alternative Names: CP-4033; Ribavirin-5'-elaidic acid ester ; UNII-4LU13X0I13Latest Information Update: 07 Nov 2021
Price :
$50
*
At a glance
- Originator Clavis Pharma
- Developer Translational Therapeutics
- Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
- Mechanism of Action Eukaryotic initiation factor 4E inhibitors; Oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thyroid cancer
Most Recent Events
- 17 Nov 2013 No development reported - Preclinical for Thyroid cancer in USA (unspecified route)
- 09 Oct 2013 Clavis Pharma is now called Aqualis
- 02 Sep 2011 Ribavirin elaidate receives Orphan Drug status for Thyroid cancer in the USA